Morphotek, Inc. Announces Initiation Of A Phase I Study For MORAb-066

    Morphotek, Inc. Announces Initiation Of A Phase I Study For MORAb-066

PR Newswire

EXTON, Pa., June 25, 2013

EXTON, Pa., June 25, 2013 /PRNewswire/ --Morphotek®, Inc., a subsidiary of
Eisai Inc., announced today that the Sarah Cannon Research Institute in
Nashville, Tennessee has opened enrollment in a Phase I clinical study with
MORAb-066 in patients with advanced or metastatic breast, pancreatic,
colorectal or non-small cell lung cancer (adenocarcinoma) malignancies. The
open-label Phase I study will assess the safety, tolerability and
pharmacokinetics of MORAb-066 administered with weekly intravenous infusions.

MORAb-066 is a humanized monoclonal antibody that targets tissue factor (TF),
which is a protein whose role under normal conditions is to support blood
coagulation. In cancer, it has been shown that TF is a membrane-bound antigen
expressed by tumor endothelial cells that is hypothesized to play a role in
promoting tumor angiogenesis and growth. Morphotek obtained exclusive
worldwide rights to develop and commercialize this antibody from Janssen
Biotech, Inc. 

"We are excited to have initiated this Phase I study of MORAb-066," stated
Nicholas Nicolaides, Ph.D., President and CEO of Morphotek. "New agents are
needed for cancer treatment and our strategy of using collaborations with
leading research institutions provides us opportunities to develop novel
medicines that target disease-specific pathways."

"MORAb-066's target as an inhibitor of TF may eventually offer a new approach
in our efforts to develop cancer treatments," said Johanna Bendell, M.D.
director of Sarah Cannon's GI Cancer Research Program. "We are delighted to
have the opportunity to collaborate in the evaluation of this novel agent."

Further information on the clinical study can be found at, study number NCT 01761240.

About Morphotek
Morphotek^®, Inc., a subsidiary of Eisai Inc., is a biopharmaceutical company
specializing in the development of protein and antibody products through the
use of a novel and proprietary gene evolution technology. The technology has
been successfully applied to a broad variety of cell lines and organisms to
yield genetically diverse offspring that are suitable for pharmaceutical
product development in the areas of antibody therapeutics, protein
therapeutics, product manufacturing, drug target discovery, and improved
output traits for commercial applications. The company is currently focusing
its platform on the development and manufacturing of therapeutic antibodies
for the treatment of cancer, inflammation and infectious disease. For more
information, please visit 

About Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to
patients and their families, and helping to increase the benefits health care
provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co.,
Ltd., our passionate commitment to patient care is the driving force behind
our efforts to help address unmet medical needs. We are a fully integrated
pharmaceutical business with discovery, clinical, manufacturing and marketing
capabilities. Our key areas of commercial focus include oncology and specialty
care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more
about Eisai Inc., please visit us at

Eisai Inc. has affiliates that are part of a global product creation
organization that includes R&D facilities in Massachusetts, New Jersey, North
Carolina and Pennsylvania, as well as a global demand chain organization that
includes manufacturing facilities in Maryland and North Carolina. Eisai's
global areas of R&D focus include neuroscience; oncology; metabolic disorders;
vascular, inflammatory and immunological reaction; and antibody-based

About Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is a global strategic research
organization focusing on advancing therapies for patients. It is one of the
largest clinical research programs, conducting community-based clinical trials
in oncology and cardiology through affiliations with a network of more than
700 physicians in the United States and United Kingdom. Additionally, SCRI
offers management, regulatory and other research support services to drug
development sponsors and strategic investigator sites. For more information,
please visit

Contacts: Media and Investor        Media Inquiries       Investor Inquiries
          Rod Dausch                Lynn Kenney           Alex Scott
          Morphotek, Inc.           Eisai Inc.            Eisai Inc.
          610-423-6111              201-746-2294          201-746-2177

SOURCE Morphotek, Inc.

Press spacebar to pause and continue. Press esc to stop.